Protocol for the impact of medication therapy management on efficacy and safety of postoperative anticoagulation therapy in patients with colorectal cancer: an open-label, prospective and randomized clinical trial [0.03%]
药物治疗管理对结直肠癌术后抗凝疗效和安全性影响的方案：一项开放性、前瞻性随机临床试验
Jieling Mao,Zhikun Liang,Min Gao et al.
Jieling Mao et al.
Background: Anticoagulants, classified as high-risk medications, are commonly used and are associated with significant potential harm in postoperative patients. Patients with colorectal cancer (CRC) are among the most sus...
Randomized Controlled Trial
Chinese clinical oncology. 2026 Feb;15(1):6. DOI:10.21037/cco-25-111 2026
Jingqi Hu,Hailiang Tang,Ming Xu et al.
Jingqi Hu et al.
Abducens schwannoma is relatively very rare, and accounts for only about 1% of all intracranial schwannomas. Here, we report microsurgical resection of a rare case of cisternal-segment abducens schwannoma in a female patient. Upon physical ...
Analysis of the clinical features and surgical treatment of small intestinal stromal tumor: a retrospective study based on 119 cases [0.03%]
小肠间质瘤的临床特征及手术治疗分析(基于119例病例的回顾性研究)
Linxiang Xu,Congxian Yang,Jing Liu et al.
Linxiang Xu et al.
Background: Small intestinal stromal tumors (SISTs) are mesenchymal neoplasms originating from the interstitial cells of Cajal in the small intestine. As a distinct subtype of gastrointestinal stromal tumors (GISTs), SIST...
Temporal evolution of liver cancer etiology in China, 1990-2021: insights from the Global Burden of Disease Study 2021 [0.03%]
中国1990-2021年肝癌发病原因的时空演变：全球疾病负担研究（2021）启示
Tao Luo,Senxin Wang,Shangru Yang et al.
Tao Luo et al.
Background: Primary liver cancer constitutes a significant public health issue in China. The hepatitis B virus (HBV) remains the primary etiological agent of liver cancer, whereas the role of metabolic liver diseases, par...
A bibliometric analysis of 2000-2024 on interventional therapy for liver cancer and tumor immune microenvironment [0.03%]
2000-2024年肝癌介入治疗与肿瘤免疫微环境的文献计量分析
Siqin Liang,Ming Li,Zhiliang Xu et al.
Siqin Liang et al.
Background: In recent years, the tumor immune microenvironment (TIME) has been gradually emphasized in liver cancer interventional therapy. The present study aimed to evaluate the current research hotspots and development...
Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990-2041: an ecological study [0.03%]
基于生态学研究的中国1990～2041年膀胱癌和肾癌疾病负担流行趋势及未来预测
Jianxu Yuan,Shengjie Yu,Ji Zheng
Jianxu Yuan
Background: Bladder cancer (BCa) and kidney cancer are increasingly significant public health concerns in China. However, comprehensive analyses of their long-term disease burden trends and future projections remain limit...
Gleason score discrepancies between prostate biopsy and radical prostatectomy in prostate cancer patients: a retrospective single-center analysis [0.03%]
前列腺癌患者经皮活检与根治性前列腺切除术 Gleason评分差异的单中心回顾性分析
Yuhan Chen,Jun Luo,Qifei Dong et al.
Yuhan Chen et al.
Background: Prostate cancer (PCa) is one of the leading malignancies in males worldwide. Accurate assessment of Gleason scores (GSs) preoperatively is critical for making appropriate treatment decisions. However, GS discr...
Efficacy and safety of apatinib for the treatment of extensive-stage small cell lung cancer in Chinese patients: a single-arm systematic review and meta-analysis [0.03%]
阿帕替尼治疗广泛期小细胞肺癌中国患者的疗效和安全性：单臂系统综述和荟萃分析
Tingting Nan,Ruina Cai,Siheng Lian et al.
Tingting Nan et al.
Background: At present, the prognosis for patients with extensive-stage small cell lung cancer (ES-SCLC) has remained poor. If standard treatment for ES-SCLC fails, these patients face rapid disease progression and high m...
Meta-Analysis
Chinese clinical oncology. 2025 Dec;14(6):67. DOI:10.21037/cco-25-34 2025
Enhancing audiometric surveillance in head and neck cancer patients undergoing cisplatin-based chemoradiation [0.03%]
顺铂放化疗的头颈部癌症患者的听觉监测增强
Aurora Mirabile,Raffaele Addeo
Aurora Mirabile
Metronomic capecitabine plus aromatase inhibitor as initial therapy in HR-positive HER2-negative metastatic breast cancer: a low-cost and easily implementable option [0.03%]
作为HR阳性HER2阴性转移性乳腺癌初始治疗的他莫昔芬联合卡培他滨：一种低成本且易于实施的方案
Dana Narvaez,Gerneiva T Parkinson,Stephanie L Graff
Dana Narvaez